Adjuvant Probiotics of Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 Attenuate Glycemic Levels and Inflammatory Cytokines in Patients With Type 1 Diabetes Mellitus

Chung-Hsing Wang, Hung-Rong Yen, Wen-Li Lu, Hsieh-Hsun Ho, Wen-Yang Lin, Yi-Wei Kuo, Yen-Yu Huang, Shin-Yu Tsai, Hung-Chih Lin, Chung-Hsing Wang, Hung-Rong Yen, Wen-Li Lu, Hsieh-Hsun Ho, Wen-Yang Lin, Yi-Wei Kuo, Yen-Yu Huang, Shin-Yu Tsai, Hung-Chih Lin

Abstract

Introduction: Type 1 diabetes mellitus (T1DM) is characterized by autoimmune destruction of pancreatic β cells. Previous study has discovered that probiotic strains residing in the gut play essential roles in host immune regulation. However, few clinical results demonstrated probiotic would actually benefit in attenuating glycated hemoglobin (HbA1c) along with inflammatory cytokine levels of the T1DM patients and analyzed their gut microbiota profile at the same time. In this clinical trial, we evaluated the therapeutic efficacy of probiotics on HbA1c along with inflammatory cytokine levels of T1DM patients to determine an alternative administration mode for T1DM medication. The probiotics changed T1DM gut microbiota profile will be measured by next-generation sequencing (NGS).

Research design and methods: A randomized, double-blind, placebo-controlled trial was performed at China Medical University Hospital. T1DM patients between 6 and 18 years of age were enrolled. 27 patients were administered regular insulin therapy plus capsules containing probiotic strains Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 daily for 6 months, and 29 patients were administered insulin therapy without extra probiotic supplement as placebo group. The variations of fasting blood glucose and HbA1c in these patients were analyzed. In addition, serum levels of inflammatory cytokines and anti-inflammatory cytokine were assessed using enzyme-linked immunosorbent assay. Patients' stool microbiota were all subjects to NGS analysis.

Results: NGS data showed elevated populations of Bifidobacterium animalis, Akkermansia muciniphila and Lactobacillus salivarius in the gut of patients with T1DM who were taking probiotics. Patients with T1DM who were administered probiotics showed significantly reduced fasting blood glucose levels compared with the before-intervention levels. The HbA1c levels of the patients also improved after administration of probiotics. The concentrations of IL-8, IL-17, MIP-1β, RANTES, and TNF-α were significantly reduced and were associated with an increased TGF-β1 expression after probiotic intervention. The persistence effect of glycemic control and immunomodulation were observed even 3 months after discontinuation of the probiotics.

Conclusions: Here, we found that conventional insulin therapy plus probiotics supplementation attenuated T1DM symptoms than receiving insulin treatment only. Probiotics supplementation with insulin treatment changed gut microbiota and revealed better outcome in stabilizing glycemic levels and reducing HbA1c levels in patients with T1DM through beneficial regulation of immune cytokines.

Clinical trial registration: ClinicalTrials.gov, identifier NCT03880760.

Keywords: T1DM; glycemic levels; gut microbiota; immune cytokines; probiotic.

Conflict of interest statement

Author H-HH, W-YL, Y-WK, Y-YH, and S-YT were employed by Bioflag Biotech Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Wang, Yen, Lu, Ho, Lin, Kuo, Huang, Tsai and Lin.

Figures

Figure 1
Figure 1
Analysis of microbiota dispersion (%) among patients with T1DM. The data present microbiota changes at the phylum (A), genus (B), and species levels (C). The amount of microbiota was normalized with that observed before intervention. Statistical difference between the probiotic group and placebo is indicated by a white two-way arrow. Placebo group: T1DM patients receive regular insulin treatment but no additional probiotic supplementation. Probiotic group: T1DM patients receive regular insulin treatment with additional probiotic supplementation.
Figure 2
Figure 2
The levels of Glucose AC (A), HbA1c (B), inflammatory cytokines (C) and anti-inflammatory cytokine TGF-β1 (D) of patients with T1DM after 6-month probiotic intervention were normalized with before-intervention levels and then compared with the placebo group. Statistical differences between probiotic and placebo groups were shown as *P < 0.05, **P < 0.01, and ***P < 0.001. Placebo group: T1DM patients receive regular insulin treatment but no additional probiotic supplementation. Probiotic group: T1DM patients receive regular insulin treatment with additional probiotic supplementation.

References

    1. Rosen CJ, Ingelfinger JR. Traveling Down the Long Road to Type 1 Diabetes Mellitus Prevention. N Engl J Med (2019) 381(7):666–7. doi: 10.1056/NEJMe1907458
    1. Lacy PE. The Pancreatic Beta Cell. Structure and Function. N Engl J Med (1967) 276(4):187–95. doi: 10.1056/NEJM196701262760401
    1. Kalyva E, Malakonaki E, Eiser C, Mamoulakis D. Health-Related Quality of Life (HRQoL) of Children With Type 1 Diabetes Mellitus (T1DM): Self and Parental Perceptions. Pediatr Diabetes (2011) 12(1):34–40. doi: 10.1111/j.1399-5448.2010.00653.x
    1. Dokken BB. The Pathophysiology of Cardiovascular Disease and Diabetes: Beyond Blood Pressure and Lipids. Diabetes Spectr (2008) 21(3):160–5. doi: 10.2337/diaspect.21.3.160%JDiabetesSpectrum
    1. Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of Type 1 Diabetes. Endocrinol Metab Clin North Am (2010) 39(3):481–97. doi: 10.1016/j.ecl.2010.05.011
    1. You WP, Henneberg M. Type 1 Diabetes Prevalence Increasing Globally and Regionally: The Role of Natural Selection and Life Expectancy at Birth. BMJ Open Diabetes Res Care (2016) 4(1):e000161. doi: 10.1136/bmjdrc-2015-000161
    1. Buzhor E, Leshansky L, Blumenthal J, Barash H, Warshawsky D, Mazor Y, et al. . Cell-Based Therapy Approaches: The Hope for Incurable Diseases. Regener Med (2014) 9(5):649–72. doi: 10.2217/rme.14.35
    1. Primavera M, Giannini C, Chiarelli F. Prediction and Prevention of Type 1 Diabetes. Front Endocrinol (Lausanne) (2020) 11:248:248. doi: 10.3389/fendo.2020.00248
    1. Rewers M, Ludvigsson J. Environmental Risk Factors for Type 1 Diabetes. Lancet (2016) 387(10035):2340–8. doi: 10.1016/S0140-6736(16)30507-4
    1. Korf H, Gysemans C, Overbergh L, Mathieu C. J. I. D. M. Pathogenesis of Type 1 Diabetes Mellitus: Immunologic Pathways. International Diabetes Monitor (2010) 22:121–7.
    1. Kaur N, Bhadada SK, Minz RW, Dayal D, Kochhar R. Interplay Between Type 1 Diabetes Mellitus and Celiac Disease: Implications in Treatment. Dig Dis (2018) 36(6):399–408. doi: 10.1159/000488670
    1. Makharia GK. Celiac Disease Screening in Southern and East Asia. Dig Dis (2015) 33(2):167–74. doi: 10.1159/000369537
    1. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the Normal Gut Microbiota. World J Gastroenterol (2015) 21(29):8787–803. doi: 10.3748/wjg.v21.i29.8787
    1. Han H, Li Y, Fang J, Liu G, Yin J, Li T, et al. . Gut Microbiota and Type 1 Diabetes. Int J Mol Sci (2018) 19(4):995. doi: 10.3390/ijms19040995
    1. Knip M, Honkanen J. Modulation of Type 1 Diabetes Risk by the Intestinal Microbiome. Curr Diabetes Rep (2017) 17(11):105. doi: 10.1007/s11892-017-0933-9
    1. Drexhage HA, Dik WA, Leenen PJ, Versnel MA. The Immune Pathogenesis of Type 1 Diabetes: Not Only Thinking Outside the Cell But Also Outside the Islet and Out of the Box. Diabetes (2016) 65(8):2130–3. doi: 10.2337/dbi16-0030
    1. Mishra SP, Wang S, Nagpal R, Miller B, Singh R, Taraphder S, et al. . Probiotics and Prebiotics for the Amelioration of Type 1 Diabetes: Present and Future Perspectives. Microorganisms (2019) 7(3):67. doi: 10.3390/microorganisms7030067
    1. de Oliveira GLV, Leite AZ, Higuchi BS, Gonzaga MI, Mariano VS. Intestinal Dysbiosis and Probiotic Applications in Autoimmune Diseases. Immunology (2017) 152(1):1–12. doi: 10.1111/imm.12765
    1. Shi G, Sun C, Gu W, Yang M, Zhang X, Zhai N, et al. . Free Fatty Acid Receptor 2, a Candidate Target for Type 1 Diabetes, Induces Cell Apoptosis Through ERK Signaling. J Mol Endocrinol (2014) 53(3):367–80. doi: 10.1530/JME-14-0065
    1. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. . Expert Consensus Document. The International Scientific Association for Probiotics and Prebiotics Consensus Statement on the Scope and Appropriate Use of the Term Probiotic. Nat Rev Gastroenterol Hepatol (2014) 11(8):506–14. doi: 10.1038/nrgastro.2014.66
    1. Hsieh PS, Ho HH, Hsieh SH, Kuo YW, Tseng HY, Kao HF, et al. . Lactobacillus Salivarius AP-32 and Lactobacillus Reuteri GL-104 Decrease Glycemic Levels and Attenuate Diabetes-Mediated Liver and Kidney Injury in Db/Db Mice. BMJ Open Diabetes Res Care (2020) 8(1):e001028. doi: 10.1136/bmjdrc-2019-001028
    1. Hsieh PS, Tsai YC, Chen YC, Teh SF, Ou CM, King VA. Eradication of Helicobacter Pylori Infection by the Probiotic Strains Lactobacillus Johnsonii MH-68 and L. Salivarius Ssp. Salicinius AP-32. Helicobacter (2012) 17(6):466–77. doi: 10.1111/j.1523-5378.2012.00992.x
    1. A. American Diabetes . Standards of Medical Care in Diabetes–2010. Diabetes Care (2010) 33 Suppl 1:S11–61. doi: 10.2337/dc10-S011
    1. Kawasaki E, Maruyama T, Imagawa A, Awata T, Ikegami H, Uchigata Y, et al. . Diagnostic Criteria for Acute-Onset Type 1 Diabetes Mellitus (2012): Report of the Committee of Japan Diabetes Society on the Research of Fulminant and Acute-Onset Type 1 Diabetes Mellitus. J Diabetes Investig (2014) 5(1):115–8. doi: 10.1111/jdi.12119
    1. 8 Pharmacologic Approaches to Glycemic Treatment. Standards of Medical Care in Diabetes—2018. Diabetes Care (2018) 41(Supplement 1):S73–85. doi: 10.2337/dc18-S008%JDiabetesCare
    1. American Diabetes Association . 6. Glycemic Targets: Standards of Medical Care in Diabetes-2021. Diabetes Care (2021) 44(Suppl 1):S73–84. doi: 10.2337/dc21-S006
    1. Ho J, Reimer RA, Doulla M, Huang C. Effect of Prebiotic Intake on Gut Microbiota, Intestinal Permeability and Glycemic Control in Children With Type 1 Diabetes: Study Protocol for a Randomized Controlled Trial. Trials (2016) 17(1):347. doi: 10.1186/s13063-016-1486-y
    1. UK Prospective Diabetes Study (UKPDS) Group. Intensive Blood-Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes (UKPDS 33). Lancet (1998) 352(9131):837–53. doi: 10.1016/S0140-6736(98)07019-6
    1. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. . Association of Glycaemia With Macrovascular and Microvascular Complications of Type 2 Diabetes (UKPDS 35): Prospective Observational Study. BMJ (2000) 321(7258):405–12. doi: 10.1136/bmj.321.7258.405
    1. Diabetes Canada Clinical Practice Guidelines Expert C, McGibbon A, Adams L, Ingersoll K, Kader T, Tugwell B. Glycemic Management in Adults With Type 1 Diabetes. Can J Diabetes (2018) 42(Suppl 1):S80–7. doi: 10.1016/j.jcjd.2017.10.012
    1. Atkinson MA, Eisenbarth GS. Type 1 Diabetes: New Perspectives on Disease Pathogenesis and Treatment. Lancet (2001) 358(9277):221–9. doi: 10.1016/S0140-6736(01)05415-0
    1. Ruan Y, Sun J, He J, Chen F, Chen R, Chen H. Effect of Probiotics on Glycemic Control: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials. PloS One (2015) 10(7):e0132121. doi: 10.1371/journal.pone.0132121
    1. Asemi Z, Zare Z, Shakeri H, Sabihi SS, Esmaillzadeh A. Effect of Multispecies Probiotic Supplements on Metabolic Profiles, Hs-CRP, and Oxidative Stress in Patients With Type 2 Diabetes. Ann Nutr Metab (2013) 63(1-2):1–9. doi: 10.1159/000349922
    1. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V. Probiotic Yogurt Improves Antioxidant Status in Type 2 Diabetic Patients. Nutrition (2012) 28(5):539–43. doi: 10.1016/j.nut.2011.08.013
    1. Shakeri H, Hadaegh H, Abedi F, Tajabadi-Ebrahimi M, Mazroii N, Ghandi Y, et al. . Consumption of Synbiotic Bread Decreases Triacylglycerol and VLDL Levels While Increasing HDL Levels in Serum From Patients With Type-2 Diabetes. Lipids (2014) 49(7):695–701. doi: 10.1007/s11745-014-3901-z
    1. Ito C, Mito K, Hara H. Review of Criteria for Diagnosis of Diabetes Mellitus Based on Results of Follow-Up Study. Diabetes (1983) 32(4):343–51. doi: 10.2337/diab.32.4.343
    1. World Health Organization . Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia: Report of a WHO/IDF Consultation. Geneva:WHO Press; (2006).
    1. Shih CT, Yeh YT, Lin CC, Yang LY, Chiang CP. Akkermansia Muciniphila is Negatively Correlated With Hemoglobin A1c in Refractory Diabetes. Microorganisms (2020) 8(9):1360. doi: 10.3390/microorganisms8091360
    1. Karvonen AM, Sordillo JE, Gold DR, Bacharier LB, O'Connor GT, Zeiger RS, et al. . Gut Microbiota and Overweight in 3-Year Old Children. Int J Obes (Lond) (2019) 43(4):713–23. doi: 10.1038/s41366-018-0290-z
    1. Xu Y, Wang N, Tan HY, Li S, Zhang C, Feng Y. Function of Akkermansia Muciniphila in Obesity: Interactions With Lipid Metabolism, Immune Response and Gut Systems. Front Microbiol (2020) 11:219. doi: 10.3389/fmicb.2020.00219
    1. Biagi E, Franceschi C, Rampelli S, Severgnini M, Ostan R, Turroni S, et al. . Gut Microbiota and Extreme Longevity. Curr Biol (2016) 26(11):1480–5. doi: 10.1016/j.cub.2016.04.016
    1. Groele L, Szajewska H, Szypowska A. Effects of Lactobacillus Rhamnosus GG and Bifidobacterium Lactis Bb12 on Beta-Cell Function in Children With Newly Diagnosed Type 1 Diabetes: Protocol of a Randomised Controlled Trial. BMJ Open (2017) 7(10):e017178. doi: 10.1136/bmjopen-2017-017178
    1. Marcial GE, Ford AL, Haller MJ, Gezan SA, Harrison NA, Cai D, et al. . Lactobacillus Johnsonii N6.2 Modulates the Host Immune Responses: A Double-Blind, Randomized Trial in Healthy Adults. Front Immunol (2017) 8:655. doi: 10.3389/fimmu.2017.00655
    1. Zheng P, Li Z, Zhou Z. Gut Microbiome in Type 1 Diabetes: A Comprehensive Review. Diabetes Metab Res Rev (2018) 34(7):e3043. doi: 10.1002/dmrr.3043
    1. Ahmadi Z, Arababadi MK, Hassanshahi G. CXCL10 Activities, Biological Structure, and Source Along With its Significant Role Played in Pathophysiology of Type I Diabetes Mellitus. Inflammation (2013) 36(2):364–71. doi: 10.1007/s10753-012-9555-1
    1. Wuyts A, Proost P, Lenaerts JP, Ben-Baruch A, Van Damme J, Wang JM. Differential Usage of the CXC Chemokine Receptors 1 and 2 by Interleukin-8, Granulocyte Chemotactic Protein-2 and Epithelial-Cell-Derived Neutrophil Attractant-78. Eur J Biochem (1998) 255(1):67–73. doi: 10.1046/j.1432-1327.1998.2550067.x
    1. Schall TJ. Biology of the RANTES/SIS Cytokine Family. Cytokine (1991) 3(3):165–83. doi: 10.1016/1043-4666(91)90013-4
    1. Meagher C, Arreaza G, Peters A, Strathdee CA, Gilbert PA, Mi QS, et al. . CCL4 Protects From Type 1 Diabetes by Altering Islet Beta-Cell-Targeted Inflammatory Responses. Diabetes (2007) 56(3):809–17. doi: 10.2337/db06-0619
    1. Chatzigeorgiou A, Harokopos V, Mylona-Karagianni C, Tsouvalas E, Aidinis V, Kamper EF. The Pattern of Inflammatory/Anti-Inflammatory Cytokines and Chemokines in Type 1 Diabetic Patients Over Time. Ann Med (2010) 42(6):426–38. doi: 10.3109/07853890.2010.495951
    1. Rouvier E, Luciani MF, Mattei MG, Denizot F, Golstein P. CTLA-8, Cloned From an Activated T Cell, Bearing AU-Rich Messenger RNA Instability Sequences, and Homologous to a Herpesvirus Saimiri Gene. J Immunol (1993) 150(12):5445–56.
    1. Wan YY, Flavell RA. The Roles for Cytokines in the Generation and Maintenance of Regulatory T Cells. Immunol Rev (2006) 212:114–30. doi: 10.1111/j.0105-2896.2006.00407.x
    1. You S, Thieblemont N, Alyanakian MA, Bach JF, Chatenoud L. Transforming Growth Factor-Beta and T-Cell-Mediated Immunoregulation in the Control of Autoimmune Diabetes. Immunol Rev (2006) 212:185–202. doi: 10.1111/j.0105-2896.2006.00410.x
    1. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al. . Inflammatory Cytokine Concentrations are Acutely Increased by Hyperglycemia in Humans: Role of Oxidative Stress. Circulation (2002) 106(16):2067–72. doi: 10.1161/
    1. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, et al. . C-Peptide is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve Beta-Cell Function: Report of an ADA Workshop, 21-22 October 2001. Diabetes (2004) 53(1):250–64. doi: 10.2337/diabetes.53.1.250
    1. Akirav EM, Lebastchi J, Galvan EM, Henegariu O, Akirav M, Ablamunits V, et al. . Detection of Beta Cell Death in Diabetes Using Differentially Methylated Circulating DNA. Proc Natl Acad Sci USA (2011) 108(47):19018–23. doi: 10.1073/pnas.1111008108
    1. Ballan R, Saad SMI. Characteristics of the Gut Microbiota and Potential Effects of Probiotic Supplements in Individuals With Type 2 Diabetes Mellitus. Foods (2021) 10(11):2528. doi: 10.3390/foods10112528

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj